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ARTICLE
BCL11A Haploinsufficiency Causes
an Intellectual Disability Syndrome
and Dysregulates Transcription
Cristina Dias,1,17 Sara B. Estruch,2,17 Sarah A. Graham,2 Jeremy McRae,1 Stephen J. Sawiak,3,4
Jane A. Hurst,5 Shelagh K. Joss,6 Susan E. Holder,7 Jenny E.V. Morton,8 Claire Turner,9
Julien Thevenon,10,11 Kelly Mellul,12 Gabriela Sa´nchez-Andrade,1 Ximena Ibarra-Soria,1
Pelagia Deriziotis,2 Rui F. Santos,13 Song-Choon Lee,1,14 Laurence Faivre,10,11 Tjitske Kleefstra,15
Pentao Liu,1 Mathew E. Hurles,1 DDD Study,1 Simon E. Fisher,2,16,18,* and Darren W. Logan1,19,*
Intellectual disability (ID) is a common condition with considerable genetic heterogeneity. Next-generation sequencing of large co-
horts has identified an increasing number of genes implicated in ID, but their roles in neurodevelopment remain largely unexplored.
Here we report an ID syndrome caused by de novo heterozygous missense, nonsense, and frameshift mutations in BCL11A, encoding a
transcription factor that is a putative member of the BAF swi/snf chromatin-remodeling complex. Using a comprehensive integrated
approach to ID disease modeling, involving human cellular analyses coupled to mouse behavioral, neuroanatomical, and molecular
phenotyping, we provide multiple lines of functional evidence for phenotypic effects. The etiological missense variants cluster in
the amino-terminal region of human BCL11A, and we demonstrate that they all disrupt its localization, dimerization, and transcrip-
tional regulatory activity, consistent with a loss of function. We show that Bcl11a haploinsufficiency in mice causes impaired cogni-
tion, abnormal social behavior, and microcephaly in accordance with the human phenotype. Furthermore, we identify shared aberrant
transcriptional profiles in the cortex and hippocampus of these mouse models. Thus, our work implicates BCL11A haploinsufficiency
in neurodevelopmental disorders and defines additional targets regulated by this gene, with broad relevance for our understanding of
ID and related syndromes.
Introduction
Currently, there are more than 820 genes known to
contribute to intellectual disability (ID) and associated
childhood neurodevelopmental disorders.1 Up to 2.5%
of individuals are diagnosed with mild to severe ID,2
characterized by low cognitive ability and impaired adap-
tive behavior with onset during early development.
Genes disrupted in ID and other neurodevelopmental
disorders are enriched for those involved in chromatin
remodeling and transcriptional regulation.3,4 Remark-
ably, more than 1% of cases are attributed to mutations
disrupting genes of the BRG1/BRM-associated factor
(BAF) swi/snf chromatin-remodeling complex, suggest-
ing that BAFopathies represent an important recurrent
cause of ID.2,5,6
The Deciphering Developmental Disorders (DDD) study
has contributed significantly to the understanding of ID
through the identification of novel associated genes on a
large scale.6 The DDD identified de novo missense muta-
tions in BCL11A (MIM: 606557, also known as CTIP1
and EVI9) in several individuals with ID. Its protein prod-
uct has been implicated as a member of the mammalian
BAF swi/snf chromatin remodeling complex in human
T cells and post-natal mouse brain.7 BCL11A, a transcrip-
tional factor with C2H2 zinc finger DNA-binding motifs,
has been extensively studied for its role in hematopoiesis
and malignancy8–12 and as a transcriptional repressor of
fetal hemoglobin,13 but its contributions to neurodevelop-
ment are more poorly understood.14–17 A role for BCL11A
in normal human brain function is inferred by the
presence of chromosomal microdeletions at 2p15–p16.1
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encompassing the gene in individuals with speech sound
disorder18 and with more severe ID,19 as well as by a recent
association with autism spectrum disorder (ASD).20 More-
over, biallelic ablation of Bcl11a in murine model brains
at mid-gestation leads to deficient migration of cortical
projection neurons.16,21 Notably, the microdeletions thus
far associated with neurodevelopmental phenotypes have
the potential to affect coding regions and non-coding reg-
ulatory elements of BCL11A18,19,22,23 and might also have
effects on neighboring genes.24 Therefore, sufficiency of
monoallelic BCL11A disruption alone has not been
demonstrated to be a cause of ID to date, nor has its effects
on brain development and regulation been explored.
In addition to missense mutations, we also identified
several de novo nonsense and frameshift mutations in
BCL11A in individuals with ID in the DDD and other co-
horts. In this study, we aimed to address the following
questions. What are the features of a putative clinical syn-
drome associated with disruption of BCL11A?What are the
effects of BCL11A missense mutations on functions of the
encoded proteins? Are the identified mutations sufficient
to cause the clinical phenotype seen in affected individ-
uals? And, as a transcriptional regulator, what are the mo-
lecular effects of heterozygous BCL11A mutations?
We identify shared clinical features in all individuals,
including persistence of fetal hemoglobin (HbF). Our as-
says in cell-based models support the hypothesis that the
missense mutations result in loss of function of the
mutated proteins in vivo. Hence, we determine that ID is
the result of haploinsufficiency of BCL11A through
different mutational mechanisms. We show that haploin-
sufficiency of Bcl11a alone in a mouse model is sufficient
to recapitulate key cognitive, behavioral, and neuroana-
tomical phenotypes present in affected individuals. In
this haploinsufficient mouse model, we identify transcrip-
tional dysregulation of the hippocampus and cortex, brain
regions that correlate with neuroanatomical and behav-
ioral phenotypes.
Together, we present an integrated approach to disease
modeling in rare ID syndromes including cellular, behav-
ioral, neuroanatomical, and molecular characterization,
and further implicate the BAF complex in neurodevelop-
mental disorders.
Subjects and Methods
Human Subjects
The Deciphering Developmental Disorders (DDD) study has UK
Research Ethics Committee approval (10/H0305/83, granted by
the Cambridge South REC, and GEN/284/12 granted by the Re-
public of Ireland REC). Written informed consent was received
from participants prior to inclusion in the study.
The PARI (Regional Action Plan for Innovation) 2011 study was
approved by the regional ethics committee and funded by the
Regional Council of Burgundy and Dijon University Hospital.
Informed consent was received from individuals prior to inclusion
in the study.
Where exome sequencing was performed in the context of
routine healthcare services, informed consent for the diagnostic
procedure was obtained.
Exome Sequencing and Statistical Assessment
Affected individuals were identified through the DDD project (in-
dividuals 1–6), through clinical exome sequencing (individuals 7
and 8), and through the Dijon University Hospital PARI 2011
study (individual 9). Whole-exome sequencing and de novo
variant annotation were performed as previously described.6,25
Functional annotation of variants was performed using the En-
sembl Variant Effect Predictor (VEP)26 consequence predictions.
The BCL11A de novo variants studied here, together with two
loss-of-function de novo variants identified in individuals with
ASD,20 were analyzed for significance in the context of 4,295
DDD study trios, 2,206 clinical exome trios, 50 PARI 2011 trios,
and 6,138 trios from other reported exome-sequencing studies of
developmental disorders.20,25,27–36 Statistical assessment of the
BCL11A variants was performed using an analytical method
combining evidence for enrichment for de novo mutations over
that expected for gene mutation rate and cohort size,6 clustering
of mutations,6 and Human Phenotype Ontology (HPO) term sim-
ilarity between DDD individuals, as described.37
Assessment of Enrichment of De Novo Mutations
Expected null mutation rates for BCL11A for different functional
classes of variants were obtained from reported estimates.38 The
loss-of-functionmutation rate was estimated by summing the mu-
tation rates of nonsense, canonical splice sites, and frameshift var-
iants. The functionalmutation rate was estimated by summing the
loss-of-function mutation rate with the rate of missense variants
and in-frame indels. The loss-of-function and functional mutation
rates were multiplied by the number of gene transmissions (twice
the number of probands) to give the total expected number of mu-
tations given the number of probands sequenced. The expected
number of mutations in each class was assumed to be the mean
of a Poisson distribution, and the probability of drawing from
that distribution a number of mutations equal or greater than
the observed number of mutations was calculated. A combined
functional de novo statistic was calculated by using Fisher’s
method to combine p values from enrichment of functional muta-
tions with clustering of missense mutations. The loss-of-function
enrichment and the combined functional statistic were compared
and the better performing model was selected. The resulting p
value was adjusted for the use of two models by Bonferroni
correction.
Assessment of Clustering of De Novo Mutations
Exon coordinates and sequences for BCL11A were retrieved from
Ensembl. Nucleotide mutation rates in trinucleotide contexts
were provided by Kaitlin Samocha and Mark Daly. De novo
missense mutations were randomly sampled, weighted by the
context-specific mutation rates, matching the number of sampled
mutations to the number of known de novos. The de novos were
assessed for their tendency to cluster within close proximity to
each other. The proximity was calculated as the geometric mean
coding distance between all the possible de novo pairs. The ex-
pected distribution of proximity was assumed as the distribution
of proximity for sampled de novos from 1,000,000 simulations.
The p value was estimated as the proportion of simulated proxim-
ities less than or equal to the observed proximity.
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Assessment of Phenotypic Similarity
Probands in the DDD study had phenotypes systematically re-
corded by clinical geneticists using terms from the Human Pheno-
type Ontology (HPO). For pairs of HPO terms, we determined the
information content (IC) for the most informative common
ancestor of the two terms. The IC was calculated as the negative
logarithm of the probability of the terms’ usage within the 4,295
DDD probands (including descendant terms’ usage). The similar-
ity of terms between two individuals was estimated as the
maximum IC from pairwise comparisons of the individuals’
HPO terms. The score for a set of n probands was estimated as
the sum of all the pairwise scores. The null distribution was simu-
lated by randomly sampling 100,000 sets of n probands and calcu-
lating scores as above. The p value was estimated as the proportion
of simulated scores greater than or equal to the observed score.
DNA Constructs
The coding sequences of BCL11A-S (GenBank: NM_138559),
BCL11A-L (GenBank: NM_018014), and NONO (GenBank:
NM_001145408) were amplified from human fetal brain cDNA us-
ing the primers in Table S1 and cloned into pCR2.1-TOPO (Invitro-
gen). The missense mutations were introduced using the Quik-
Change Lightning SDM kit (Agilent) and the primers in Table
S2. For expression of fusion proteins with Renilla luciferase, YFP,
and mCherry, cDNAs were subcloned into the pLuc, pYFP, and
pmCherry expression vectors, respectively, which have been
described previously, using the BamHI and XbaI sites.39,40 For
the mammalian one-hybrid assay, a vector for expression of
BCL11A fused in frame with the yeast GAL4 DNA-binding domain
was created by cutting and re-ligating pBIND (Promega) at the ClaI
sites to remove the Renilla luciferase expression cassette.Wild-type
and mutant forms of BCL11A-L were subcloned into the BamHI
and XbaI sites of this vector. A reporter plasmid was generated
by inserting a KpnI-NcoI fragment of pG5luc (Promega) contain-
ing five GAL4 binding sites and a minimal adenovirus major late
promoter into the vector pGL4.23 (Promega), which contains a
codon-optimized firefly luciferase gene. A plasmid containing Re-
nilla luciferase downstream of the herpes simplex virus thymidine
kinase promoter (pGL4.74, Promega) was used for normalization.
Cell Culture
HEK293 cells (ECACC cat# 85120602, RRID: CVCL_0045) were
cultured in DMEM supplemented with 10% FBS. Transfections
were performed using GeneJuice (Merck-Millipore) according to
the manufacturer’s instructions.
Western Blotting
Cells were transfected in 6-well plates and cultured for 48 hr. Cells
were lysed for 10 min at 4C with 100 mM Tris (pH 7.5), 150 mM
NaCl, 10mMEDTA, 0.2% Triton X-100, 1% PMSF, and protease in-
hibitor cocktail. Cell lysates were cleared by centrifugation at
10,000 3 g for 3 min at 4C. Proteins were resolved on 10% SDS-
polyacrylamide gels and transferred to PVDF membranes using a
TransBlot Turbo blotting apparatus (Bio-Rad). Membranes were
blocked in phosphate-buffered saline containing 5% non-fat
milk powder and 0.1% Tween-20 and then incubated overnight
at 4C with primary antibody. The following antibodies were
used: anti-GFP (Clontech cat# 632380, RRID: AB_10013427;
1:8,000, for YFP constructs) and anti-b-actin (Sigma cat# A5441,
RRID: AB_47644; 1:10,000). After washing, membranes were incu-
bated with horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit IgG for 45 min at room temperature. Proteins were
visualized using Novex ECL Chemiluminescent Substrate Reagent
Kit (Invitrogen) and a ChemiDoc XRSþ imaging system (Bio-Rad).
Cellular Assay Fluorescence Microscopy
Cells were seeded on coverslips coated with poly-L-lysine. Cells
were cultured for 30 hr post-transfection and then fixed with
methanol. Fluorescence images were acquired using Zeiss Axiovert
A-1 or Axio Imager 2 fluorescence microscopes with ZEN Image
software.
BRET Assay
The BRET assay has been described in detail elsewhere.40 In brief,
cells were transfected in white, clear-bottomed 96-well plates, in
triplicate, with 6 fmol Renilla luciferase fusion expression plasmid
and 6 fmol YFP fusion expression plasmid (total mass of DNA was
adjusted to 60 ng with filler plasmid). Renilla luciferase or YFP with
a nuclear localization signal were used as controls. Cells were
cultured for 48 hr post-transfection. Enduren luciferase substrate
(Promega) was added at a final concentration of 60 mM, and cells
were cultured for a further 4 hr. Luminescence was measured in
a TECAN Infinite F200PRO microplate reader using the Blue1
and Green1 filters.
Mammalian One-Hybrid Assay
Cells were transfected in white, clear-bottomed 96-well plates, in
triplicate, with 8.5 fmol pBIND-BCL11A, 5 fmol firefly luciferase
reporter plasmid, and 2 fmol Renilla luciferase normalization
plasmid (total mass of DNA was adjusted to 60 ng with filler
plasmid). Cells were cultured for 48 hr post-transfection. Firefly
and Renilla luciferase activities were measured using the Dual
Luciferase Reporter Assay (Promega).
Animal Models
Housing and breeding of mice and experimental procedures were
carried out under the authority of a UK Home Office license (80/
2472), after review by the Animal Welfare and Ethical Review
Body of the Wellcome Trust Sanger Institute.
Molecular, behavioral, and imaging studies were performed us-
ing mutant mice harboring a Bcl11a gene trap upstream of exon
4, disrupting all major isoforms: knockout first, conditional-ready
LacZ reporter allele (Bcl11aLacZ; Figures S1A and S1B).12,41 Mice
were kept on a C57BL/6(50%);129S5(50%) background. Immuno-
histochemistry was performed on F1 mice from a cross between
Bcl11aþ/LacZ mice and mice harboring the Bcl11atm1Peli eGFP re-
porter allele (Bcl11aþ/tm1Peli and Bcl11aLacZ/tm1Peli).42 All mice
used were from colonies maintained at the Research Support Facil-
ity of the Wellcome Trust Sanger Institute.
Imaging
Adult mice (aged 165 1 week) were anesthetized and then trans-
cardially perfused with 20mL of ice-cold PBS followed by 4% para-
formaldehyde (PFA). The skull was detached and skin removed.
The brain was kept in loco. Skulls were transferred into PBS after
24 to 48 hr and kept at 4C before imaging.
MRI Image Acquisition
Brains were scanned using a Bruker PharmaScan 47/16 system at
4.7T with a manufacturer-provided birdcage transmit-receive
coil. The imaging protocol was fast spin echo (scan parameters:
repetition time 2,000 ms, effective echo time 16 ms, echo train
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length 4, bandwidth 32 kHz, matrix 2563 1923 128, field of view
1.79 3 1.34 3 0.90 cm3, resolution 70 mm isotropic with two
averages).
MRI Tensor-Based Morphometry
Brains were segmented into gray and white matter portions and
registered using the SPMMouse toolbox43 with SPM8 (Wellcome
Trust Centre for Neuroimaging, University College London) and
the DARTEL registration toolbox.44 Jacobian determinants from
the registration process were smoothed with a 400 mm Gaussian
kernel and tested with an F-test between groups to produce
voxel-wisemaps for tensor-basedmorphometry. The scaling factor
from the affinematrix was used as a covariate to find differences in
volume that could not be explained by overall brain size. To con-
trol the type I error rate due to multiple comparisons, an adjusted
p value was used for a false-discovery rate at p < 0.05.
mCT
Image acquisition and reconstruction were performed on the Sky-
scan 1172 high-resolutionmicro-CT (mCT) using the standard soft-
ware provided by the manufacturer (Bruker micro-CT). 3D image
and video generation was performed with DataViewer software
(Brucker, v.1.5.1.2, May 27, 2014) using the same parameters for
all skulls (opacity adjusted, luminance adjusted, 96% red, 90%
green, 84% blue, 5% shadows, 100% emission, 50% diffuse, 25%
specular, 40 camera viewing). Measurements were obtained
blinded to genotype as described by de Carlos et al.45 and corrected
using a multiplanar visualization of reference points in sagittal,
axial, and coronal planes (described in Figure S2). Comparison
of lengths and statistical analyses (Mann-Whitney test) were per-
formed using GraphPad Prism v.6.00 (GraphPad Software).
Histology and Immunohistochemistry
All brain tissue samples were fixed through transcardial perfusion
of 4% PFA as described above. Samples were dehydrated, paraffin
embedded, and sectioned before hematoxylin and eosin, luxol
fast blue, and cresyl violet staining using standard histological
techniques.
For immunohistochemistry, perfused brain samples were cryo-
protected in 30% sucrose, embedded in OCT, and stored at
80C. Samples were sectioned at 16 mm using a LeicaCM3050S
cryostat. Sections were permeabilized with 1% Triton X and
blocked with BlockAid Blocking Solution (Thermo Fisher Scientific
cat# B10710) or rabbit serum (b-gal). Specificity of BCL11A staining
was confirmedby co-detectionofb-gal andGFP (Figure S3). Because
endogenous GFP expression was below detection, a specific
primary antibody was utilized. Primary antibodies used were
anti-BCL11A (Abcam cat# ab19489, RRID: AB_2063996; 1:250),
anti-b-gal (Abcam cat# ab9361, RRID: AB_307210; 1:1,000), and
anti-GFP (Torrey Pines Biolabs cat# TP-401, RRID: AB_10013661;
1:500). Secondary antibodies included Alexa Fluor-564 goat
anti-mouse-IgG1 (Thermo Scientific cat# A-21123, RRID:
AB_2535765), Alexa Fluor-488 goat anti-rabbit IgG (Thermo Scien-
tific cat# R-37116, RRID: AB_2556544), and Alexa Fluor-488 rabbit
anti-chicken-IgY (Jackson Immuno Research cat# 303-545-003,
RRID: AB_2339327). Slides were mounted with ProLong Gold
Antifade reagent with DAPI nuclear counterstain (Life Technolo-
gies cat# P36935). Sections were visualized and photographed on
a Leica TCS SP5/DM6000 confocal microscope with Leica Applica-
tionSuiteAdvancedFluorescence softwareor aZeissAxiovert 200M
microscope with Axiovision software.
Social Recognition Assay
For all behavioral assays described, mice were habituated to the
behavior test room for R1 hr under same light conditions as the
test. For the social recognition assay,46 group-housed test mice
(mutant and littermate wild-type controls) were habituated to
the 39 3 21 cm test arena for 10 min. On day 1 (habituation-dis-
habituation test), a conspecific anesthetized stimulus was placed
on the center of the test arena for 1 min, repeated 4 times at in-
ter-trial intervals of 10 min (Movie S1). On the 5th trial, a new
stimulus mouse was presented. On day 2, after a 24 hr interval,
the discrimination test was performed (Figure S4). The familiar
stimulus animal from trials 1–4 and a new unfamiliar mouse
were placed on opposite sides of the test arena for 2 min (Movie
S2). The amount of time the test animal spent investigating
by close-proximity sniffing, oronasal contact, or approaching
within 1–2 cm was recorded. For day 2, social discrimination pref-
erence index was calculated according to the following equation:
preference index (PI) ¼ (investigation time [s] of novel unfamiliar
stimulus  familiar stimulus)/(investigation time [s] of familiar þ
unfamiliar stimulus).
Trials were performed under red light and recordedwith an over-
head camera. The trials were scored blind to genotype by two
observers, and the average of both observations was used as the
time. Stimulus animals were subject to non-terminal anesthesia
with ketamine/xylazine (i.p. 1 g/0.1 g per kg of body weight).
Familiar stimuli were recovered with atipamezole for use in the
24 hr discrimination test. The stimulus animals were gender
matched, equal or lower weight, and different strain. 129P2/
OlaHsd,129S5/SvEvBrd mice were used for trials1–4 and 24 hr
discrimination familiar stimulus; C57BL/6 or C57BL/6;129 mice
from different breeding colonies were used for trial 5 and 24 hr
discrimination unfamiliar stimulus. Two-way ANOVA and un-
paired t test (after a D’Agostino & Pearson omnibus normality
test) were employed where indicated. Statistical analysis for all
mouse behavior experiments was performed with GraphPad Prism
v.6.00 (GraphPad Software).
Open Field Assay
Mice were placed in a 37 3 37 cm open field for 5 min under red
light. Their movements were tracked by detection of the mouse
center point using overhead infrared video cameras and auto-
mated video tracking software (Ethovision XT 8.5, Noldus Infor-
mation Technology). A 24 3 24 cm ‘‘center zone’’ was designated
with equidistant borders to the open field walls. The frequency
and time each mouse was within this center zone was recorded.
A period of movement was defined when the mouse reached a ve-
locity of 2 cm/s over two frames; a period of non-movement was
defined when velocity was lower than 1.75 cm/s over two frames.
Three-Chamber Social Behavior
The three-chamber social approach task was performed under red
light, modified from Yang et al.47 The chamber layout is presented
in Figure S4F. In brief, a test arena was divided into four quadrants;
one quadrant was sealed off, and the remaining three chambers
formed the L-shaped arena used for the test. Innate chamber
side preference was controlled for during the habituation phase
and did not show difference between genotypes (t test, p ¼
0.2144). Two arenas were used for increased throughput of
behavior experiments, and mice were randomly assigned to the
test arena. Differences between arenas were tested. In one arena,
mice showed an innate preference for the left chamber (0.15
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increase in preference index in habituation) independent of geno-
type (2-way ANOVA, per genotype p ¼ 0.2004; per arena p ¼
0.0262). Subsequent times were normalized to the innate prefer-
ence index. Mouse movements were tracked via overhead infrared
video cameras and automated video tracking software.
Test mice were habituated to the center chamber for 5 min.
Doors were then opened to the two empty side chambers and
mice were allowed to explore all three chambers for a further
5 min. Doors were re-closed and the mice were contained
briefly in the center chambers as objects were placed in the
side chambers. Identical objects—stainless steel cylindrical
containers with holes sufficiently large to contain a mouse
nose—were placed upside down in the side chambers. One ob-
ject contained a live conspecific (novel sex-matched stimulus
previously habituated to the object) that could freely move in-
side the object. Test mice then explored all three chambers for
10 min with automated movement tracking (Movie S3). The
preference index was calculated as follows: PI ¼ (time in cham-
ber with object containing a conspecific stimulus  time in
chamber with object only)/(time in chamber with object con-
taining a conspecific stimulus þ time in chamber with object
only).
RNA-Sequencing Processing and Analysis
Mice were sacrificed at 16 weeks of age. The cortex and hippocam-
pus were dissected frommale animals, snap frozen in liquid nitro-
gen, and stored at 80C. Tissue was homogenized in buffer RLT
plus with b-mercaptoethanol (10 mL/mL) using the QIAGEN
TissueLyser LT. RNA was pre-treated on gDNA eliminator columns
and then extracted on RNeasy Plus columns as per manufacturer’s
protocol (QIAGEN). Multiplexed libraries were prepared for
sequencing using Illumina RNA Library Preparation Kits as per
manufacturer’s protocol. Paired end sequencing was performed
on the Illumina HiSeq 2000 or V4 generating 75 bp reads.
Using STAR v.2.4,48 sequenced reads were realigned to an altered
version of the mouse reference genome GRCm38 (Ensembl anno-
tation release 78, December 2014) containing a pseudo-chromo-
some with the mutant neomycin cassette sequence for genotype.
The number of reads mapped to each gene was counted using the
HTSeq (v.0.6.1) count function in mode intersection-nonempty.
HTSeq count data was used as input for differential gene expres-
sion analysis using the R (v.3.2.2) DESeq2 package (v.1.9.29).49
Because samples were sequenced in three different sequencing
experiments (including both genotypes per batch), the R/Bio-
conductor sva package (v.3.16.0) was used to estimate the tech-
nical variation (seeWeb Resources). The covariates (‘‘surrogate var-
iables’’ generated by sva) were added into the DESeq2 test design.
DESeq2 uses the Benjamini-Hochberg procedure to control for
multiple testing, returning an adjusted p value (padj) for the differ-
ential gene expression. Given the exploratory nature of the anal-
ysis, the DESeq2 default significance cut-off of BH-adjusted p value
< 0.1 was used.
The top most highly expressed mitochondrial genes
were excluded from the normalized read count generation in
DESeq2, because these were highly expressed and variable be-
tween biological replicates (Ensembl: ENSMUSG00000064351,
ENSMUSG00000064370, ENSMUSG00000064341, ENSMUSG
00000064339, ENSMUSG00000064367, ENSMUSG00000064337,
ENSMUSG00000064363). For the hippocampal tissues, two wild-
type and threeBcl11aþ/ sampleswere found to be extremeoutliers
on principal component analysis and were excluded from the
differential gene expression analysis. Six samples per genotype
were used for the hippocampus and nine samples per genotype
for the cortex.
Gene Ontology
Gene ontology enrichment analysis was performed with Gene-
Trail.50 Over-representation analysis of the differentially expressed
genes was performed using parameters in Table S3 with signifi-
cance threshold, 0.1 and p values adjusted for multiple testing us-
ing the Benjamini-Hochberg FDR adjustment. In all analyses a
background comprised of only the expressed genes used for the
relevant analysis was provided.
Gene Enrichment Analysis
Enrichment for voltage gated ion channels (VGIC) was performed
using genes annotated as one of the 141 mouse VGIC in the
IUPHAR/BPS database (accessed 30 September 2015).51 ASD-
related genes were selected from the SFARI gene web portal.52 Of
the 740 genes downloaded from The Human Gene Module of
SFARI gene database (September 2015), 485 were selected based
on exclusion of genes with the following levels of evidence anno-
tated in the SFARI database: functional (only), functional negative
association (>1), genetic association (only). Of these, 481 mouse
orthologs were identified through Ensembl.53 We generated a sec-
ond subset of 75 unique human genes and 1 pseudogene from the
Gene Scoring Module of SFARI, which were annotated in the
following categories defined in the database: S (syndromic), 1
(high confidence), and 2 (strong candidate). 75 mouse orthologs
were identified through Ensembl. Analysis was performed in R
v.3.2.2.; for statistical analysis, hypergeometric test was employed
with a significant p value < 0.05. Genes used in gene enrichment
analyses above are available in Table S4.
Transcriptome Assembly
For a qualitative analysis of Bcl11a isoform and transcription start
site usage, the paired end reads aligned using STAR v.2.4.0 were
assembled into transcripts via Cufflinks v.2.2.1.54 Assembled gtf
files from different replicates for each tissue were merged via
cuffmerge including the reference annotation. Cuffquant was
employed for isoform quantification. Data visualization and
graphical representation were performed with CummeRbund
v.2.12.0.54
Results
Identification of Mutations in BCL11A in Individuals
with ID
We identified nine individuals with intellectual disability
with de novo mutations in BCL11A: three missense and
six loss of function (LoF). In the DDD study6 we identified
six individuals with de novo heterozygous variants in
BCL11A, from a total of 4,295 affected individuals studied
using whole-exome sequencing (Figure 1A; Table 1). Three
missense variants were first identified; they cluster
together in exon 2 of BCL11A (individuals 1, 2, and
3).14,15 Subsequently, we identified three novel variants
(one nonsense [individual 4] and two frameshift [individ-
uals 5 and 6]) classified26 as LoF (Figure 1C). Individual 6
also has a probably pathogenic 4.3 Mb duplication but
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was unavailable for further investigation (Table 1). Addi-
tional individuals with de novo LoF variants were identi-
fied in other developmental disorder cohorts (individuals
7–9). To evaluate their pathogenicity, we performed a sta-
tistical enrichment analysis of all these variants, along
with two further LoF variants recently identified in
ASD20,36 (individuals 10 and 11; Table 1). We find compel-
ling statistical support for an excess of mutations in
BCL11A (p ¼ 6.4 3 1015; see Subjects and Methods).
All individuals that we identified with BCL11A muta-
tions presented with global delay in developmental mile-
stones, including speech and language delay. Most individ-
uals exhibited moderate ID, though cognitive dysfunction
varies from mild (individual 1) to severe (individual 2) (Ta-
ble 1). One of the two individuals recently ascertained
through an ASD study20,36 also has severe ID (individual
10); intellectual capacity was not reported in the other. In-
dividual 2 has likewise received a diagnosis of ASD, and
four other individuals present a spectrum of behavior ab-
normalities including repetitive behavior and sensory
problems. Shared physical features among affected indi-
viduals (Figure 1D) include joint laxity (87%), strabismus
Figure 1. Clinical and Molecular Features of Individuals with BCL11A Mutations
(A) Schematic representation of the three major isoforms of BCL11A (GenBank and Ensembl transcript identifiers indicated): BCL11A-
XL (NM_022893.3, ENST00000335712), BCL11A-L (NM_018014.3, ENST00000356842), and BCL11A-S (NM_138559, ENST00000
359629). Mutations are represented on and annotated according to the BCL11A-XL isoform (NM_022893.3); predicted protein variants
are represented as follows: orange triangles, missense variants; red stars, truncating variants identified in the current study; gray stars,
variants in previously reported individuals with autism spectrum disorder. C2H2 DNA binding zinc finger domains are represented in
red; non-DNA binding zinc finger is shaded brown. The red line indicates the putative dimerization region. Putative region required
for SUMO1 recruitment is shaded gray. Proline (Pro)- and glutamate (Glu)-rich regions are shaded blue. Abbreviation is as follows: aa,
amino acids.
(B–D) Clinical features of individuals 1, 2, 4, 5, 7, 8, and 9. Individual number and predicted protein variant are indicated below the
respective photograph. Various and partly overlapping facial features of individuals withmissense (B) and loss-of-function (C)mutations
in BCL11A, including strabismus, downslanting palpebral fissures, synophrys, flat midface, thin upper lip, and full lower lip. Shared core
clinical features of all affected individuals (detailed in Table 1) are summarized in (D). The heatmap colors represent the frequency of the
feature seen, from 100% (red) to 30% (blue); frequency is calculated based on information available for each feature. Features that are
present predominantly (microcephaly, abnormal external ears) or exclusively (blue sclerae in infancy) in individuals with LoFmutations
are indicated by a red star. Abbreviations are as follows: DD, developmental delay; ID, intellectual disability; ASD, autism spectrum
disorder.
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(100%), microcephaly (55%), and thin upper lip and flat
midface (Figures 1B and 1C). 62% of affected individuals
have external ear abnormalities (Table 1), which are more
severe in individuals with nonsense and frameshift muta-
tions. Individuals 4, 5, and 6, all of whom present
nonsense or frameshift mutations, had blue sclerae in in-
fancy. As well as the BCL11A variant, individual 6 also
carries a 15q15.3q21.1 duplication, and a contribution of
this duplication to the phenotype, specifically to delayed
skeletal maturation and short stature, cannot be
excluded.55 HbF was significantly elevated in all affected
individuals in whom it was assessed, including all those
with missense mutations in BCL11A (Figure 1D, Table 1).
Notably, individual 1, carrying a missense mutation, had
HbF levels similar to those seen for individual 5, carrying
a frameshift mutation.
All LoF variants are predicted to deleteriously affect iso-
forms L (GenBank: NM_018014.3, Ensembl: ENST00000
356842) and XL (NM_022893.3, ENST00000335712) of
BCL11A (Figure 1A) through premature truncation or
frameshift and nonsense-mediated decay (annotated iso-
forms are summarized in Figure S5). All missense variants
are located in the N-terminal region of BCL11A, which is
required for homo- and heterodimerization of BCL11A iso-
forms,56 as well as for interaction with repressive nucleo-
some remodeling complexes.57 Given the known role of
the gene as a regulator of stage-specific hemoglobin expres-
sion,13 we hypothesized that the missense mutations
impair function of BCL11A and investigated functional
consequences using cell-based assays.
Missense Mutations Disrupt BCL11A Function
Our cellular assays focused on BCL11A-L and BCL11A-S
(GenBank: NM_138559, Ensembl: ENST00000359629),
the two isoforms of BCL11A reported in human brain.10
We generated mCherry and YFP-tagged versions of these
isoforms containing each of the three missense mutations
identified in affected individuals and expressed them in
HEK293 cells (Figure 1A). BCL11A-L binds to DNA in a
sequence-specific manner via two C2H2 zinc finger do-
mains (Figure 1A)8 and localizes to the nucleus. BCL11A-
S lacks the zinc finger domains and is unable to
bind to DNA, but can form heterodimers with BCL11A-L
and -XL that mediate the translocation from its predomi-
nantly cytoplasmic localization into the nucleus.8,14,15,56
BCL11A-L has predominant nuclear localization, whereas
isoform S localizes to the cytoplasm in the absence of inter-
action with L and XL isoforms.56
The mutant forms of BCL11A-L and BCL11A-S show
similar protein levels to the wild-type (Figure S6).
We found that both wild-type and mutant BCL11A-S iso-
forms are predominantly localized to the cytoplasm
(Figure 2A).8,15,58 In contrast, wild-type BCL11A-L is found
in nuclear paraspeckles, as demonstrated by its co-local-
ization with the paraspeckle-specific protein NONO,56
also recently implicated in ID.59 Strikingly, all three
missense mutations disrupt the paraspeckle distribution
of BCL11A-L, as well as its co-localization with NONO (Fig-
ures 2B and 2C). In addition, using a bioluminescence
resonance energy transfer (BRET) assay, we found that
the mutations reduce, but do not completely abolish, the
interaction of BCL11A-L with NONO (Figure 2D).40
The three missense mutations identified in affected
individuals all lie within a region encoding a putative
dimerization site in BCL11A (Figure 1A).8 We confirmed
that wild-type BCL11A-L and BCL11A-S form homo-
and heterodimers (Figures 3A, 3B, S7A, and S7B)15,56 and
that co-expression of BCL11A-L causes BCL11A-S to trans-
locate from the cytoplasm into nuclear paraspeckles
(Figure 3C).56 We found that BCL11A-L isoforms carrying
mutations have a substantially reduced interaction with
both L and S wild-type BCL11A isoforms (Figures 3A and
3B) and a reduced capacity to translocate wild-type
BCL11A-S into the nucleus (Figure 3C). Similar effects
were observed when the mutations were introduced into
BCL11A-S (Figure S7).
We used a mammalian one-hybrid assay to examine
the effects of the missense mutations on the capacity of
BCL11A to regulate transcription. BCL11A-L was fused
to the DNA-binding domain of yeast GAL4 and co-trans-
fected with a reporter plasmid containing five sequential
GAL4 binding sites upstream of a luciferase gene. Wild-
type BCL11A-L produced a ~2.5-fold activation of re-
porter transcription, an effect that was significantly
reduced for all three mutant isoforms (p < 0.05, one-
way ANOVA followed by Bonferroni post hoc test;
Figure 3D).
In summary, all three missense mutations identified in
affected individuals are associated with persistence of
HbF and show consistent deleterious effects on multiple
aspects of BCL11A molecular function, including localiza-
tion, dimerization, and transcriptional regulatory activity.
These findings indicate that the mutations yield a loss of
function of the mutant proteins in vivo, suggesting that
the associated neurodevelopmental syndrome may result
from a haploinsufficiency mechanism.
Mice with Bcl11a Haploinsufficiency Phenocopy
Features of the Human ID Syndrome
To test the hypothesis that haploinsufficiency of BCL11A is
sufficient to cause a specific neurodevelopmental syn-
drome, and to gain further insights into pathogenic mech-
anisms, we generated a Bcl11a heterozygous mouse line
containing a LacZ reporter (Figure S1, herein termed
Bcl11aþ/; see Methods).12 Mouse Bcl11a (also known as
Evi9 and Ctip1) is highly homologous to human BCL11A
(the XL isoform shows 97% cDNA sequence identity and
100% protein sequence identity between species).53
Germline biallelic loss of Bcl11a leads to perinatal lethality
inmouse models,9 though its neurodevelopmental pheno-
type has not been explored. In utero knockdown experi-
ments and conditional knockout models show that
Bcl11a is necessary for normal mouse cortical develop-
ment.9,16 However, global haploinsufficiency of Bcl11a in
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Table 1. Genetic and Clinical Characteristics of Individuals with De Novo BCL11A Mutations
Individual 1 2 3 4 5 6a 7 8 9 10b 11c
Summary
of
Features
BCL11A
mutationd
c.139A>C
(p.Thr47Pro)
c.143G>T
(p.Cys48Phe)
c.198C>A
(p.His66Gln)
c.529C>T
(p.Gln177Ter)
c.2035_2037delinsC
(p.Ser679GlnfsTer47)
c.1545delinsGGCTTC
(p.Phe515LeufsTer5)
c.1775_1776insTGG
CTCAGCGG
(p.Glu593GlyfsTer9)
c.154C>T
(p.Gln52Ter)
c.193G>T
(p.Glu65Ter)
c.1325_1325del
(p.Leu442ProfsTer37)
c.792_793insC
(p.Leu265ProfsTer3)
3
missense;
8
nonsense/
frameshift
Decipher ID 262471 262952 261658 268026 275695 280953 NA NA NA NA NA
Mutation
class
missense missense missense loss of
function
loss of function loss of function loss of function loss of
function
loss of
function
loss of function loss of function
Sex F M F F F F F F M F M 3 M, 8 F
Microcephaly e e þ þ þ þ þ e e NA NA 5/9
Intellectual
disability
mild-
moderate
moderate-
severe
moderate moderate moderate þf moderate moderate moderate severe NA 10/10
(average
moderate)
Developmental Milestones (Age of Achievement in Months)
Sat
independently
7 10 12 NA 11 NA NA 14 12 NA NA ~11
Walked
independently
20 36 24 22 45 NA NA 23 36 30 NA ~29.5
First words 22 27 36 16 NAg (80 words at
100 months)
24–30 NA (few words at
33 months)
60 36 NA (2 words at
6 years)
NA ~32
Craniofacial Features
Downslanting
palpebral
fissures
þ   þ  NA þ þ  NA NA 4/8
Epicanthus     þ NA þ  þ NA NA
Strabismus þ þ þ þ þ NA þ þ þ NA NA 8/8
Blue sclera in
infancy
   þ þ þ    NA NA 3/9
Flat midface þ þ þ þ þ NA   þ NA NA 6/8
Thin upper lip þ þ þ þ þ NA  þ þ NA NA 7/8
(Continued on next page)
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Table 1. Continued
Individual 1 2 3 4 5 6a 7 8 9 10b 11c
Summary
of
Features
Everted
lower lip
þ þ  þ  NA þ þ þ NA NA 6/8
Nose anteverted small
nares
anteverted;
full tip
  NA full tip small nares;
full tip
small nares;
full tip
NA NA 4/8
Micro/
retrognathia
     retro  retro micro NA NA 3/9
Additional
craniofacial
features
frontal
upsweep,
cleft uvula
coarse hair  small
mouth,h
high palate,
pointed chin
small mouth,
plagiocephaly,
synophrys
 large tip of the
nose, broad bridge,
flared eyebrows,
telecanthus
large tip of
the nose,
high palate
high nasal
bridge
NA NA
External ear
anomalies
  þi þj þk NA þl  þm NA NA 5/8
Additional Physical and Neurologic Features
Joint
hypermobility
þ  þ þ þ NA þ þ þ NA NA 7/8
Short stature      þ þ   NA NA 2/9
Gait
abnormalities
broad
based
broad based,
truncal
ataxia
   NA   ataxia NA NA 3/8
Other anteriorly
placed anus,
dyspraxia
fetal pads,
bilateral
coxa valga,
valgus foot
deformity
hernia repair congenital hip
dislocation,
delayed bone age
GE reflux large 2nd
metacarpals,
scoliosis
pectus
excavatum
NA NA
Behavioral Features
ASD  þ    NA    þ þ 3/10
Repetitive
behavior
þ þ þ þ  NA     NA 4/9
Other
behavior
problems
emotional
lability
recurrent
hand
flapping
sensory
abn., self-
injurious
behavior
recurrent
hand
flapping/
biting
none reported NA none reported anxiety,
eating
disorder
none
reported
attention
deficit
NA 6/9
Sleep
disturbance
 þ þ þ  NA    þ NA 4/9
(Continued on next page)
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Table 1. Continued
Individual 1 2 3 4 5 6a 7 8 9 10b 11c
Summary
of
Features
Additional Investigations
MRI slightly
reduced
WM
volume
small CV NA normal VM NA NA atrophy of
the superior
CV
mild
hypoplasia
of the CC
NA NA
Hemoglobin
F %
20.8% 8% 8.7% NA 26.3% NA NA 3.1% 8.6% NA NA 6/6
Abbreviations are as follows: GE, gastroesophageal; ASD, autism spectrum disorder; Abn, abnormalities; WM, white matter; VM, ventriculomegaly; CV, cerebellar vermis; CC, corpus callosum; NA, not available. Ascertainment: individuals
1 to 6, the DDD study (1 to 3 reported in previous DDD study,6 4 to 6 identified subsequently); individuals 7 and 8, clinical exome sequencing; individual 9, PARI 2011 study.
aIndividual 6 has an additional probable pathogenic copy number variation (4.3 Mb duplication: dup15q15.3q21.1).
bMutation reported by de Rubeis et al.20
cMutation reported by Iossifov et al.36
dBCL11A mutations are annotated to transcript NM_022893.3, ENST00000335712 (GRCh37).
eOFC measured between percentiles 9 and 25.
fSeverity unknown.
gNo words at 28 months.
hMicrostomia, with intercomissural distance% 2 SD.
iUnilateral (left) flat helix, prominent anti-crus.
jBilateral microtia (< 2 SD), asymmetric low-set ears, with overfolded and cupped helix, attached earlobes.
kLow-set ears with overfolded helixes and attached earlobes.
lThick, overfolded helixes.
mDysplastic, posteriorly rotated ears.
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brain development and function, most relevant to the hu-
man disorder described here, has not been previously
investigated in animal models. We first used our reporter
mouse model to confirm Bcl11a expression in developing
brain from embryonic day E10.5, with highest expression
in the forebrain between E12.5 and E14.5 (Figures S1A
and S1B). Central nervous system expression persists
throughout the post-natal period in the cortex, hippocam-
pus, olfactory bulb, and, to a lesser extent, in the cere-
bellum (Figure S1C). In the hippocampus, BCL11A local-
izes intensely to granule cell layers of the dentate gyrus
and principal cell layers CA1, CA2, and CA3 (Figures S1D
and S1E). Within the adult neocortex, localization spans
layers II to VI. Although they do not show overt morpho-
logical differences, Bcl11aþ/mice appear to have a shift in
Bcl11a localization toward deeper cortical layers relative to
more superficial layers (Figure S8).
We next investigated whether murine haploinsuffi-
ciency of Bcl11a phenocopies the human individuals car-
rying BCL11A mutations. Microcephaly is a feature of
BCL11A-associated ID (Figure 1, Table 1), particularly in
individuals heterozygous for complete LoF mutations.
We performed ex vivo imaging of whole mouse heads
using magnetic resonance imaging (MRI) tensor-based
morphometry followed by voxel-based quantification of
brain volume (Figures 4A and 4B). Overall brain volume
is significantly decreased in Bcl11aþ/ mice, affecting
both gray and white matter (p ¼ 1.3 3 105, two-tailed
F-test corrected for multiple comparisons with FDR-
adjusted p < 0.05) (Figures 4A and 4B). Next, we normal-
ized by overall brain volume per genotype to investigate
whether specific substructures had a greater effect.43
We found a greater decrease in the volume of regions
that anatomically correspond to the limbic system—the
hippocampus (corresponding to CA1, CA2, CA3, and
the fimbria), corpus callosum, the posterior cortical
amygdaloid nuclei, regions of the ventral and midline
thalamic nuclei—and parts of the cerebellum, including
regions of the superior vermis (see Allen Brain Atlas
in Web Resources) (Figures 4C and S2 and Movie S4).
Micro-computed tomography (mCT) revealed that skull
morphology is similar in Bcl11aþ/ mice and their
A
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Figure 2. BCL11A Missense Substitutions Disrupt Protein Local-
ization
(A) Fluorescence micrographs of HEK293 cells transfected with
wild-type (WT) or mutant short isoform of BCL11A (BCL11A-S;
GenBank: NM_138559, Ensembl: ENST00000359629) fused to
mCherry (red). Nuclei were stained with Hoechst 33342 (blue).
(B) Fluorescence micrographs of HEK293 cells transfected with
wild-type or mutant long isoform of BCL11A (BCL11A-L;
NM_018014.3, ENST00000356842) fused tomCherry (red). Nuclei
were stained with Hoechst 33342 (blue).
(C) Fluorescencemicrographs of cells transfected with wild-type or
mutant BCL11A-L fused to mCherry (red) and NONO fused to YFP
(green). Nuclei were stained with Hoechst 33342 (blue).
Scale bars represent 10 mm.
(D) Bioluminescence resonance energy transfer (BRET) assay for
interaction of wild-type or mutant BCL11A-L with NONO.
HEK293 cells were transfected with BCL11A-L fused to Renilla
luciferase, and NONO fused to YFP. Values are mean corrected
BRET ratios 5 SEM (n ¼ 3, *p < 0.05, **p < 0.01, ***p < 0.001,
one-way ANOVA followed by Bonferroni post hoc correction).
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wild-type littermates, consistent with the absence of major
congenital malformations (Figure 4D, Movies S5 and S6).
However, the Bcl11aþ/ skulls are significantly smaller in
width (MannWhitney p¼ 0.008 and p¼ 0.032, for bi-tem-
poral and interzygomatic distances, respectively) but not
in length (p ¼ 0.31) (Figure 4E).
To investigate potential impairments in behavior,
learning, and memory, we tested the Bcl11aþ/ mice in
Figure 3. BCL11A Missense Substitutions Disrupt Protein Dimerization and Transcriptional Regulation
(A) BRET assay for interaction of mutant BCL11A-L (GenBank: NM_018014.3, Ensembl: ENST00000356842) with wild-type
(WT) BCL11A-L. HEK293 cells were transfected with wild-type or mutant BCL11A-L fused to Renilla luciferase (donor) and wild-
type BCL11A-L fused to YFP (acceptor). The control donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET
ratios5 SEM (n ¼ 3, ***p < 0.001, one-way ANOVA followed by Bonferroni post hoc correction).
(B) BRET assay for interaction of mutant BCL11A-L with wild-type BCL11A-S (NM_138559, ENST00000359629). HEK293 cells were
transfected with wild-type or mutant BCL11A-L fused to Renilla luciferase (donor) and wild-type BCL11A-S fused to YFP (acceptor).
Values are mean corrected BRET ratios 5 SEM (n ¼ 3, *p < 0.05, ***p < 0.001; one-way ANOVA followed by Bonferroni post hoc
correction).
(C) Fluorescence micrographs of HEK293 cells transfected with wild-type or mutant BCL11A-L fused to YFP (green), together with wild-
type BCL11A-S fused to mCherry (red). Nuclei were stained with Hoechst 33342 (blue). Scale bar represents 10 mm.
(D) Mammalian one-hybrid assay for BCL11A-L transcriptional regulatory activity. HEK293 cells were transfected with wild-type or
mutant BCL11A-L fused to the DNA-binding domain of GAL4, together with a firefly luciferase reporter plasmid containing GAL4
binding sites, and a Renilla luciferase normalization plasmid. Values are mean firefly luciferase activity normalized to Renilla luciferase
activity5 SEM (n ¼ 3), expressed relative to the control (***p < 0.001, one-way ANOVA followed by Bonferroni post hoc correction).
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social and activity paradigms.46 Inmousemodels a conspe-
cific recognition assay can be used to test hippocampal-
mediated cognitive processes,60 using their natural pro-
pensity to investigate unfamiliar over familiar animals
(Figures 5A–5C and S4A; see Subjects and Methods). On
day 1 of the assay, both Bcl11aþ/mice andwild-type litter-
mates investigated, then habituated and dishabituated to
anesthetized stimulus mice (Figure 5B). In a discrimination
test 24 hr later, unlike wild-type mice, the Bcl11aþ/
mice were unable to differentiate between the familiar
Figure 4. Neuroanatomical Imaging of
Mouse Brain Reveals Microcephaly
Abbreviations are as follows: þ/þ, wild-
type; þ/, Bcl11aþ/$
(A) Total brain volume in mm3 is signifi-
cantly decreased in mutant mice (mean
volumes: 457 mm3 in wild-type;
384 mm3 in Bcl11aþ/ mice; p ¼ 1.3 3
105 two-tailed F test corrected for multi-
ple comparisons by controlling the false-
discovery rate at q < 0.05).
(B) 3D reconstructions of average MRI vol-
umes for wild-type (blue) and Bcl11aþ/
(pink) mice.
(C) 3D reconstruction of heterozygous
brain MRI; regions depicted in pink are
significantly smaller in Bcl11aþ/ mice af-
ter normalization for total brain volume.
Arrows indicate orientation: blue, dorsal;
green, rostral; black, ventral.
(D) 3D reconstruction of representative
wild-type and Bcl11aþ/ skulls demon-
strating normal cranial morphology and
reduced cranial size.
(E) Cranial measurements in mm are
decreased in heterozygous mice (Mann-
Whitney test, *p< 0.05; **p< 0.01). Boxes
indicate 25th, mean, and 75th percentiles;
whiskers indicate minimum and
maximum values.
MRI: Bcl11aþ/þ, n ¼ 11; Bcl11aþ/, n ¼ 5.
mCT: Bcl11aþ/þ, n ¼ 5; Bcl11aþ/, n ¼ 5.
and unfamiliar stimulus mice (t test
p ¼ 0.710; mean preference index
[PI] ¼ 0.0204 5 0.099), indicating
impairment of long-term social mem-
ory (Figures 5C and S4B).
Some affected individuals with het-
erozygous BCL11A mutations have
exhibited increased physical activity
(repetitive behavior and hand flap-
ping), so we tested Bcl11aþ/ mice in
an open field environment. The
Bcl11aþ/ mice displayed hyper-loco-
motion across the open field, with
significant increase in the number of
transversals and time in center (Fig-
ures S4C and S4D).
Because 30% of individuals show
ASD (and overall 67% present some
type of behavioral phenotype; Table
1), we sought to investigate the effects of haploinsuffi-
ciency on social behavior in ourmousemodel. The conspe-
cific recognition assay showed that the mutant mice did
not display an overall decreased investigation time for
novel stimuli (Figures 5B and 5C), and dishabituation is
consistent with intact olfaction (Figure 5B). Therefore, we
performed a three-chamber social approach assay, widely
used as a test for ASD-like phenotypes in rodent
models.61 Consistent with their behavior in the open field
assay (Figures S4C and S4D), Bcl11aþ/ mice show
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increased activity throughout the length of the test, with
increased number of transversions between chambers
(Figure S4G). Both genotypes have similar number of trans-
version in the first 2 min of the test, however, showing
equal motivation to investigate novelty. Although overall
time spent in the side chambers is not different between
genotypes (Figure S4H), wild-type mice significantly prefer
a chamber with a conspecific compared to an empty object
(mean PI ¼ 0.285 5 0.04; paired t test per chamber for
wild-types p < 0.0001; Figure 5). In contrast, Bcl11aþ/
Figure 5. Bcl11aþ/ Mice Present with a Cognitive and Behavioral Phenotype
(A) Social recognition assay: diagram of test arenas.
(B) On day 1, mice were tested for habituation-dishabituation to a conspecific (Bcl11aþ/þ, n ¼ 11; Bcl11aþ/, n ¼ 12). Both genotypes
show decline in investigation of the same stimulus mouse (black) over four trials, with recovery on presentation of a novel stimulus
mouse on trial 5 (pink): two-way ANOVA for trial 4 versus 5, ***p < 0.0001 for trial, with no significant interaction or difference per
genotype (p ¼ 0.112, ns). No significant difference between genotypes on post hoc t test (Bcl11aþ/þ versus Bcl11aþ/, p ¼ 0.637). Values
are mean time in seconds (s)5 SEM.
(C) On a discrimination test 24 hr later, Bcl11aþ/ animals are unable to discriminate between the familiar (presented on trials 1–4 of day
1) and novel unfamiliar (green) stimulus, unlike wild-types (2-way ANOVA, significant interaction, p ¼ 0.007; post hoc t test per geno-
type: Bcl11aþ/þ, ***p ¼ 0.0005; Bcl11aþ/, p ¼ 0.71, ns).
(D and E) Three-chamber social behavior test. Heatmaps of automated tracking recordings of a representative Bcl11aþ/þ and a Bcl11aþ/
mouse; the color gradient represents time in that location: red (maximum) to blue (minimum).
(D) On habituation to empty chambers (5 min in center þ 5 min in all three), there is no preference for left or right chamber in either
genotype (p ¼ 0.414).
(E) Mice were then tested for preference for a novel object (cylinder) with a conspecific versus novel object only. The dashed white circles
indicate the novel objects introduced: one empty cylinder, one containing a conspecific mouse represented in light gray.
(F) Bcl11aþ/mice show decreased preference for the chamber containing the object with a conspecific compared to wild-type. Boxplot
of the preference index (PI) shows significantly less preference for the novel object with the conspecific in Bcl11aþ/ mice. Unpaired t
test, ***p ¼ 0.0005; Bcl11aþ/þ, n ¼ 12; Bcl11aþ/, n ¼ 16.
For box and whisker plots (C and F), boxes indicate 25th, median, and 75th percentiles; whiskers indicate minimum and maximum
values.
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mice continue equal exploration throughout the test; they
have a significantly decreased preference (t test for PI, mu-
tants versus wild-types; p ¼ 0.0005), spending a similar
amount of time in both chambers (mean PI¼ 0.017; paired
t test per chamber for mutants p ¼ 0.063; Figures 5F, S4H,
and S4I).
Mice with Bcl11aHaploinsufficiency Have Significant
Transcriptional Deregulation in the Cortex and
Hippocampus
Next, we used a genome-wide transcriptomic approach to
obtain evidence that BCL11A is involved in transcrip-
tional regulation in the mouse brain and to identify
candidate pathways involved in disease pathophysiology.
We performed RNA sequencing of cortex and hippocam-
pus, two brain structures that are enriched for Bcl11a
expression and are implicated in the neuroanatomical
and behavioral phenotypes that we describe above. Re-
sults of the transcriptomic analysis are detailed in Table
S3. For the cortex, we identified 608 differentially ex-
pressed (DE) genes in Bcl11aþ/ mice compared to wild-
type littermates (Benjamini-Hochberg [BH] adjusted p
value with 10% FDR), of which 157 (25.8%) were upregu-
lated and 451 (74.2%) downregulated (Figure 6A) as a
consequence of haploinsufficiency. Among the DE genes,
we identified significant enrichment of genes involved
with syndromic ASD (p ¼ 0.047) from the Gene Scoring
Module of SFARI, and genes with functional evidence
for ASD from the SFARI Human Gene Module (p ¼
0.029; see Methods).
Figure 6. Bcl11aþ/ Mice Have Altered Gene Expression Profiles in Cortex and Hippocampus
(A and B) MA plots of differential gene expression between Bcl11aþ/ and Bcl11aþ/þ cortex (A) and hippocampus (B). The x-axis is the
log10 average expression of all samples (normalized counts); the y-axis is DESeq2’s shrinkage estimation of log2 fold changes between
genotypes. Each gene is represented as a dot; significantly differentially expressed genes (BH-adjusted p value < 0.1) are highlighted
in red. n ¼ 9 per genotype for cortex; n ¼ 6 per genotype for hippocampus.
(C) Comparison of DESeq2’s shrinkage estimation of log2 fold changes of genes in both tissues. Red dots represent genes with significant
differential expression in both tissues; yellow dots represent genes differentially expressed in the cortex only, and blue in the hippocam-
pus only; gray dots represent genes not differentially expressed in either tissue (BH-adjusted p value < 0.1).
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For the hippocampus we identified 442 DE genes,
including 183 (41.4%) upregulated and 259 (58.6%) down-
regulated (Figure 6B, Table S3) due to haploinsufficiency.
Gene ontology analysis revealed overlapping categories
in both tissues (Figure S9), including ion channel activity
and transport. We analyzed specific enrichment for genes
encoding voltage gated ion channels,51 as they are associ-
ated with both ASD and ID,2,62 and found significant
enrichment in the hippocampus (p ¼ 0.004) and an in-
crease just below the significance threshold in the cortex
(p ¼ 0.051). These changes were predominantly downre-
gulation (Table S3). DE genes from the BAF complex were
also identified in the hippocampus: downregulation of
Smarcd1 (padj ¼ 0.0020) of the neural progenitors-specific
BAF, and of Actl6b (padj ¼ 0.0095), which encodes a
neuronal specific BAF complex protein.63
Within the gene ontology-enriched category of ‘‘cell
recognition’’ in the cortex, we identified reciprocal upregu-
lation of the Roundabout (Robo) receptor gene Robo1
(padj ¼ 0.0744) and downregulation of Robo3 (padj ¼
0.002). In both tissues we also found evidence for involve-
ment of other genes of the semaphorin-plexin pathway,
putatively regulated by Bcl11a and involved in neuronal
migration and polarity and development of neuronal
circuitry.16,64 Upregulation of semaphorins Sema3d
(cortex, padj ¼ 0.0037) and Sema3e (hippocampus,
padj ¼ 0.0047) was accompanied by reciprocal down-
regulation of the class3 semaphorin cell surface receptor
Plxnd1 in both tissues (padj ¼ 0.0246, padj ¼ 0.0038,
respectively).
We performed de novo transcript assembly to test
whether haploinsufficiency of Bcl11a alters the relative
expression of its different gene isoforms. We identify
transcription start sites (TSS) and sequence corresponding
to the annotated isoforms: L (GenBank: NM_016707,
Ensembl: ENSMUST00000000881), XL (NM_001242934,
ENSMUST00000109514), XS (NM_001159290, ENSMUST
00000118955), and S (NM_001159289, ENSMUST00000
109516), all of which are predicted to contain all or part
of the putative N-terminal dimerization region.8,53 At the
transcript level, isoforms L and XS are the most abundant
transcripts in both mouse cortex and hippocampus
(Figure S10 and Table S4), with a small relative increase
of L in proportion to XS in Bcl11aþ/ mice. The S isoform
expression level is low but fully preserved in both geno-
types. We provide evidence for a previously underappreci-
ated expression of the Bcl11a-XS isoform usage. Impor-
tantly, the apparent preservation of expression of the S
isoform in haploinsufficient cortex and hippocampus sug-
gests a fundamental role of this isoform in the adult brain.
Finally, given that both tissues share Bcl11a isoform us-
age and have well-correlated transcriptome-wide expres-
sion patterns, we compared the patterns of differential
expression between the two brain loci (Figure S11). All 69
genes that showed significant differential expression in
both structures are dysregulated in the same direction.
Indeed, of the 981 DE genes in either the cortex or the hip-
pocampus, 89.3% (876) show the same direction of change
in both tissues (Figures 6C and S11). This shared gene
expression repertoire in the brain regions implicated in
morphological, cognitive, and behavioral phenotypes sup-
ports the biological significance of these DE genes under-
pinning the Bcl11aþ/ phenotype.
Discussion
Herewe identify and phenotypically characterize an ID syn-
drome in individuals withmissense and truncating BCL11A
mutations.We demonstrate that themissense variants have
consistent deleterious effects on BCL11A localization,
dimerization, and transcriptional regulatory activity.
Together with the clinical observation that affected individ-
uals with such mutations have elevated HbF similar to
loss-of-function mutations and previously identified in in-
dividuals with chromosomal microdeletions encompassing
BCL11A,22,23 our data support the hypothesis that these N
terminus missense mutations result in a loss of BCL11A
function in vivo.
The functional studies of the BCL11A missense muta-
tions suggest that they are hypomorphic alleles, where
the loss of function may not be complete. This could
explain the similar but milder phenotypes seen in the indi-
viduals with missense mutations, as compared to what is
observed in individuals with truncations, where loss of
function of the affected allele is expected to be complete.
These experiments also support the hypothesis that the
N terminus of BCL11A is involved in protein dimerization.
Notably, the DNA-binding domains of BCL11A isoforms
remain intact with these mutations but functional transac-
tivation of transcription is impaired. Thus, cell-based assays
and clinical and hematological features indicate the impor-
tance of protein-protein interactions for BCL11A’s role in
regulating gene expression. This implies that the N termi-
nus region of BCL11Ahas anunderappreciated significance
for transcriptional repression of fetal hemoglobin.
The clinical and cellular findings are consistent with
a dosage-mediated phenotypic spectrum, with increased
severity and syndromic features in individuals with trun-
cating mutations, including blue sclerae, microcephaly,
and external ear dysplasia. Although the affected individ-
uals do not present recognizable dysmorphic features, the
presence of mild dysmorphism with ID and persistence of
fetal hemoglobin define a clinical syndrome, with the latter
providing a valuable diagnostic tool. BCL11A has previ-
ously been proposed as a susceptibility gene for ASD.20
However, we note that despite a high frequency of behavior
abnormalities, only 30% of affected individuals fulfill diag-
nostic criteria for ASD, although all have cognitive impair-
ment. Although it is possible that this reflects an over-repre-
sentation due to ascertainment bias, it is important to note
that individuals ascertained through ASD also have ID,20
whereby ASD is a variable feature of the BCL11A-intellec-
tual disability syndrome.
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Microdeletions at 2p15–p16.1 encompassing BCL11A
and adjacent genes/genomic regions have been associated
with ID accompanied by variable additional features ab-
sent in, or of greater severity than, those in individuals
with missense and LoF mutations. Genitourinary anoma-
lies are identified in half of patients,65–70 and camptodac-
tyly is also a common feature.66,68,70–73 Telecanthus, a
feature of almost all individuals with microdeletions, is
observed in only one individual with a LoF muta-
tion.19,23,65–69,71–73 CNS anomalies are detected in half of
individuals, and of greater severity than those seen in the
individuals presented here, including cortical dysplasia,69
abnormalities of the corpus callosum,65,67,68,71 white mat-
ter involvement,68 cerebellar hypoplasia,19,71 hypoplasia
of the pons,19 and optic nerve hypoplasia.66,69 The small-
est microdeletions include, in one case, an adjacentmiRNA
gene,19 and in the other, a region centromeric to BCL11A
with a putative transcription enhancer site.18 In the
latter report, the individual had two additional CNVs (du-
plications at 2q13 and 6p25.3) of unknown significance.
In individuals with microdeletions, the contribution of
haploinsufficiency or disruption of contiguous genes,
disruption of coding and non-coding regulatory elements,
or positional effects is not clear. The lack of additional mal-
formations in individuals with missense and LoF muta-
tions in BCL11A (Table 1) indicates that adjacent genes
or regulatory regions contribute to those features and
that BCL11Amay be a defining gene for the developmental
delay/ID phenotypes of individuals with microdeletions.
Mutations in BCL11A therefore cause a distinct ID
syndrome.
The recapitulation of affected individual phenotypes in
a mouse model with heterozygous loss of function of
Bcl11a confirms our hypothesis that haploinsufficiency
of this gene alone is sufficient to cause neurodevelopmen-
tal deficits, supporting its role in brain development.
Using social- and activity-based paradigms, we investi-
gated potential effects on behavior, learning, and memory.
We demonstrated that the Bcl11aþ/mousemodel displays
normal novelty-seeking behavior but shows long-term so-
cial memory defects, impaired sociability, and increased
physical activity. In addition to decreased overall brain
size, we identified an overrepresentation of the limbic sys-
tem (namely hippocampus and amygdala) among specific
mouse brain regions that are more severely affected. These
data together indicate that the individuals’ de novo
BCL11Amutations underlie their cognitive and behavioral
phenotypes.
Given Bcl11a’s established role as a known transcription
factor8,11 and its association with the BAF swi/snf
chromatin remodeling complex,7 we hypothesized that
the phenotype could be mediated by transcriptional
dysregulation. We combined cognitive assessment and
morphometry to select brain structures most severely
affected by haploinsufficiency for large-scale transcrip-
tomic analysis to investigate the genes regulated by
Bcl11a in these structures. We identified large-scale tran-
scriptional dysregulation in both cortex and hippocam-
pus of Bcl11aþ/ mice, with broad over-representation of
genes involved in ion transport, membrane trafficking,
and neuronal signaling. Interestingly, even though
BCL11A is better known for its transcriptional repressor
properties,11,13 we findmore genes downregulated in hap-
loinsufficient brains, particularly in the cortex. This may
be the result of downstream effects on targets that are
not directly regulated by BCL11A DNA binding, or tran-
scriptional regulation through a compromise of BAF com-
plex function.
Several members of the BAF swi/snf complex have been
implicated in mammalian neurodevelopment.74 In the
mutant hippocampus, we find downregulation of Smarcd1
of the embryonic stem cell and neural progenitors-specific
BAF complexes (esBAf and npBAF, respectively), essential
for embryonic stem cell differentiation to neuroecto-
derm,75 and of Actl6b. Recruitment of Actl6b accompanies
the differentiation of progenitors into neurons.76 Actl6b is
highly specific to (but not essential for) the neuronal BAF
complex (nBAF), associated with post-mitotic neuron
morphogenesis and maturation.76 Deficiency of Actl6b
has also been associated with long-term, but not short-
term, memory defects in mouse models.63 Given the
microcephaly present in some of the affected individuals
and the reduced brain size and skull width in the mouse
model, this could be suggestive of decreased neuronal pro-
liferation or reduced survival of the post-natal neurogenic
population or of post-mitotic neurons as seen postnatally
in biallelic loss of Bcl11a.16 Further studies are required to
distinguish between these possible mechanisms in the
heterozygous brain.
The differentially expressed genes are significantly en-
riched for those annotated as involved in ASD, transmem-
brane transport, and ion channel genes (Table S3).52 There
is a considerable overlap of genes involved in ID and
ASD.6,20 These transcriptional changes in a Bcl11aþ/
mouse model support the hypothesis that converging mo-
lecular mechanisms underlie both disorders.
Several molecular pathways function to control axonal
growth and guidance, providing cues through cell surface
and secreted molecules. These include ephrins, netrins,
repulsive guidance molecules, and proteins of the sema-
phorin-plexin and slit-robo signaling pathways (reviewed
by Van Battum et al.).77 Importantly, they are also regula-
tors of synaptic assembly and refinement, which high-
lights their role in postnatal brain regulation.
Our results further implicate regulation of class 3 sema-
phorins by BCL11A. Class 3 semaphorins are secreted mol-
ecules that interact with plexin transmembrane receptors
to regulate axon guidance, with additional roles in cell
migration, vascular and lymphatic development, tumor
growth and suppression, and immunologic response.77–80
BCL11A transcriptionally represses the semaphorin
Sema3c in radially migrating neurons during embryonic
cortical development.16 However, Bcl11a-dependent post-
natal differentiation and survival does not require
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SEMA3C,16 suggesting that time-sensitive interactions of
BCL11A with other targets or proteins may contribute to
developmental regulation of cortical migration. We find
evidence for dysregulation of semaphorin-plexin signaling
in the post-natal cortex and hippocampus of Bcl11aþ/
mice. Upregulation of Sema3d (in cortex) and Sema3e (in
hippocampus) of our haploinsufficient mice is accompa-
nied by reciprocal downregulation of the plexin receptor
Plxnd1. SEMA3D regulates axon-axon interaction,79 and
SEMA3E/Plexin-D1 signaling has been implicated in fore-
brain axonal guidance,81 synapse formation of cortical
neurons,82 and regulation of Cajal-Retzius cell migration
in the developing cortex.83 Class 3 semaphorins act as
Plexin-D1-mediated axonal repellents or attractants,
requiring and dependent on the presence of different neu-
ropilin co-receptors.77 Unlike SEMA3C and SEMA3D,
SEMA3E appears to be able to also bind Plexin-D1 in the
absence of neuropilin-1.80
The slit-robo signaling pathway has equally been
implicated in axon guidance and angiogenesis.84 We
find opposing differential expression of Robo3 (up) and
Robo1 (down), consistent with previous observations of
suppression of ROBO1 by ROBO3 in commissural axons.
ROBO3 regulates the number, migration, and differentia-
tion of cortical interneurons,85 whereas ROBO1 has been
shown to regulate migration of cortical neurons, notably
through regulation of semaphorin signaling,86 and has
been implicated in language-related disorders.87 Thus,
we identify significant effects of Bcl11a haploinsuffi-
ciency on expression of guidance molecules. Although
further studies are required to understand the role of
the class3/semaphorin and slit/robo pathways in the
post-natal brain, these findings suggest that BCL11A
has a broader role in post-natal synaptic regulation and
neuronal and/or vascular morphogenesis of the brain
than previously recognized.
Overall, our data suggest that there is an ongoing molec-
ular phenotype inBcl11a-associated ID that is not restricted
to early development and involves multiple post-natal mo-
lecular pathways underlying cognitive impairment and
behavioral defects. These findings raise both enthusiasm
and caution with regards to therapeutic opportunities. On
theonehand, the identificationofdynamicpost-natal tran-
scriptional dysregulation suggests that there may be thera-
peutic potential to modulate the ongoing phenotype. On
the other, it raises concern with regards to the inactivation
of BCL11A as a target for hemoglobinopathies.88 Given the
broad transcriptional effects of reducing BCL11A dose in
the brain, any therapeutic, even if restricted to erythroid
lineages, would require caution.
In summary, we identify genes and pathways altered in
the BCL11A haploinsufficient post-natal brain, suggesting
non-linear dosage sensitivity of transcriptional targets or
of interacting protein complexes such as the BAF com-
plex.7 Together, our observationsunderscore the importance
of BCL11A dosage inmammalian brain development and as
a cause of a previously undescribed BAFopathy syndrome.
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